Cargando…

A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain

SARS-CoV-2, the novel coronavirus responsible for the ongoing COVID-19 pandemic, has been spreading rampantly. The global scientific community has responded rapidly to understand immune correlates of protection to develop vaccines and immunotherapeutics against the virus. The major goal of this mini...

Descripción completa

Detalles Bibliográficos
Autores principales:	Niu, Ling, Wittrock, Kathryn N., Clabaugh, Gage C., Srivastava, Vikram, Cho, Michael W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8113771/ https://www.ncbi.nlm.nih.gov/pubmed/33995366 http://dx.doi.org/10.3389/fimmu.2021.647934

Ejemplares similares

Induction of Potent and Durable Neutralizing Antibodies Against SARS-CoV-2 Using a Receptor Binding Domain-Based Immunogen
por: Srivastava, Vikram, et al.
Publicado: (2021)

Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern
por: Favorskaya, Irina A., et al.
Publicado: (2022)

A Stabilized, Monomeric, Receptor Binding Domain Elicits High-Titer Neutralizing Antibodies Against All SARS-CoV-2 Variants of Concern
por: Ahmed, Shahbaz, et al.
Publicado: (2021)

Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern
por: Deshpande, Ashlesha, et al.
Publicado: (2021)

Neutralizing Antibody Responses to SARS-CoV-2 in Recovered COVID-19 Patients Are Variable and Correlate With Disease Severity and Receptor-Binding Domain Recognition
por: Maciola, Agnieszka Katarzyna, et al.
Publicado: (2022)

Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants
por: Shrestha, Lok Bahadur, et al.
Publicado: (2021)

XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants
por: Vanhove, Bernard, et al.
Publicado: (2021)

A Potent Neutralizing Nanobody Targeting the Spike Receptor-Binding Domain of SARS-CoV-2 and the Structural Basis of Its Intimate Binding
por: Yang, Jing, et al.
Publicado: (2022)

Corrigendum: XAV-19, a swine glyco-humanized polyclonal antibody against SARS-CoV-2 spike receptor-binding domain, targets multiple epitopes and broadly neutralizes variants
por: Vanhove, Bernard, et al.
Publicado: (2023)

Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies
por: Yuan, Meng, et al.
Publicado: (2021)

A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants
por: Shan, Sisi, et al.
Publicado: (2021)

Receptor-binding domain-specific human neutralizing monoclonal antibodies against SARS-CoV and SARS-CoV-2
por: Yu, Fei, et al.
Publicado: (2020)

Binding and neutralizing abilities of antibodies towards SARS-CoV-2 S2 domain
por: Gao, Xingsu, et al.
Publicado: (2022)

Neutralization of SARS‐CoV‐2 requires antibodies against conformational receptor‐binding domain epitopes
por: Gattinger, Pia, et al.
Publicado: (2021)

Nanobodies: Prospects of Expanding the Gamut of Neutralizing Antibodies Against the Novel Coronavirus, SARS-CoV-2
por: Konwarh, Rocktotpal
Publicado: (2020)

MG1141A as a Highly Potent Monoclonal Neutralizing Antibody Against SARS-CoV-2 Variants
por: Lee, Sua, et al.
Publicado: (2021)

Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain
por: Wheatley, Adam K., et al.
Publicado: (2021)

Humoral responses to the SARS-CoV-2 spike and receptor binding domain in context of pre-existing immunity confer broad sarbecovirus neutralization
por: Hauser, Blake M., et al.
Publicado: (2022)

Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection
por: Rosati, Margherita, et al.
Publicado: (2021)

Heterologous DNA-prime/protein-boost immunization with a monomeric SARS-CoV-2 spike antigen redundantizes the trimeric receptor-binding domain structure to induce neutralizing antibodies in old mice
por: Pflumm, Dominik, et al.
Publicado: (2023)

Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain
por: Chi, Xiaojing, et al.
Publicado: (2020)

Prospects of Neutralizing Nanobodies Against SARS-CoV-2
por: Chen, Fangfang, et al.
Publicado: (2021)

Combined Subcutaneous-Intranasal Immunization With Epitope-Based Antigens Elicits Binding and Neutralizing Antibody Responses in Serum and Mucosae Against PRRSV-2 and SARS-CoV-2
por: Fragoso-Saavedra, Mario, et al.
Publicado: (2022)

A highly sensitive bead-based flow cytometric competitive binding assay to detect SARS-CoV-2 neutralizing antibody activity
por: Yao, Xiangyu, et al.
Publicado: (2022)

The Effect of Mutations on Binding Interactions Between the SARS-CoV-2 Receptor Binding Domain and Neutralizing Antibodies
por: Barnes, Jonathan E., et al.
Publicado: (2021)

A novel bispecific antibody dual-targeting approach for enhanced neutralization against fast-evolving SARS-CoV-2 variants
por: Kim, Ji Woong, et al.
Publicado: (2023)

Single Domain Antibody application in bacterial infection diagnosis and neutralization
por: Qin, Qian, et al.
Publicado: (2022)

Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications
por: Abebe, Endeshaw Chekol, et al.
Publicado: (2023)

Hexamerization of Anti-SARS CoV IgG1 Antibodies Improves Neutralization Capacity
por: Pande, Kalyan, et al.
Publicado: (2022)

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
por: Weisblum, Yiska, et al.
Publicado: (2020)

A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants
por: Haslwanter, Denise, et al.
Publicado: (2021)

Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination
por: Hernández-Luis, Pablo, et al.
Publicado: (2022)

Pan-neutralizing, germline-encoded antibodies against SARS-CoV-2: Addressing the long-term problem of escape variants
por: Lunderberg, Justin Mark, et al.
Publicado: (2022)

A flow cytometry-based neutralization assay for simultaneous evaluation of blocking antibodies against SARS-CoV-2 variants
por: Egia-Mendikute, Leire, et al.
Publicado: (2022)

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
por: Chi, Xiangyang, et al.
Publicado: (2020)

Immunogenicity of SARS-CoV: the Receptor-Binding Domain of S Protein is a Major Target of Neutralizing Antibodies
por: He, Yuxian
Publicado: (2006)

A Rapid and Efficient Screening System for Neutralizing Antibodies and Its Application for SARS-CoV-2
por: Han, Xiaojian, et al.
Publicado: (2021)

Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies
por: Tada, Takuya, et al.
Publicado: (2022)

Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses
por: Schlickeiser, Stephan, et al.
Publicado: (2021)

The impact of CoronaVac on the neutralization breadth and magnitude of the antibody response to SARS-CoV-2 viruses
por: Zhang, Lu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9msed45j43mprpv5dgalnfa2b0